|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
WO2012087772A1
(en)
*
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
US9643955B2
(en)
|
2012-12-20 |
2017-05-09 |
Merck Sharp & Dohme Corp. |
2-pyridyloxy-3-nitrile-4-substituted orexin receptor antagonists
|
|
WO2014099697A1
(en)
*
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
3-ester-4-substituted orexin receptor antagonists
|
|
HUE032863T2
(en)
*
|
2013-02-07 |
2017-11-28 |
Merck Patent Gmbh |
Piridazinonamid derivatives
|
|
HRP20171302T1
(hr)
*
|
2013-02-07 |
2017-10-20 |
Merck Patent Gmbh |
Makrociklički derivati piridazinona
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
EP3092226B1
(en)
*
|
2014-01-10 |
2019-03-13 |
Aurigene Discovery Technologies Limited |
Indazole compounds as irak4 inhibitors
|
|
LT3466955T
(lt)
|
2014-01-13 |
2021-02-25 |
Aurigene Discovery Technologies Limited |
Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
|
|
US9969749B2
(en)
|
2014-09-30 |
2018-05-15 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
EP3200790B1
(en)
*
|
2014-09-30 |
2020-08-26 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
EP3200788B1
(en)
|
2014-09-30 |
2019-09-18 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
US9932350B2
(en)
|
2014-09-30 |
2018-04-03 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
JO3705B1
(ar)
*
|
2014-11-26 |
2021-01-31 |
Bayer Pharma AG |
إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
|
|
EP3233840B1
(en)
|
2014-12-16 |
2018-11-21 |
Eudendron S.r.l. |
Heterocyclic derivatives modulating activity of certain protein kinases
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
LT3286181T
(lt)
|
2015-04-22 |
2021-04-26 |
Rigel Pharmaceuticals, Inc. |
Pirazolo junginiai ir junginių gamybos bei naudojimo būdas
|
|
TW201701879A
(zh)
|
2015-04-30 |
2017-01-16 |
拜耳製藥公司 |
Ｉｒａｋ４抑制劑組合
|
|
EP3195865A1
(de)
|
2016-01-25 |
2017-07-26 |
Bayer Pharma Aktiengesellschaft |
Kombinationen von irak4 inhibitoren und btk inhibitoren
|
|
WO2017148902A1
(de)
|
2016-03-03 |
2017-09-08 |
Bayer Pharma Aktiengesellschaft |
Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
|
EP3219329A1
(en)
|
2016-03-17 |
2017-09-20 |
Bayer Pharma Aktiengesellschaft |
Combinations of copanlisib
|
|
WO2017186689A1
(en)
|
2016-04-29 |
2017-11-02 |
Bayer Pharma Aktiengesellschaft |
Synthesis of indazoles
|
|
EP3448849B1
(en)
|
2016-04-29 |
2020-05-13 |
Bayer Pharma Aktiengesellschaft |
Synthesis of indazoles
|
|
MX394560B
(es)
|
2016-06-01 |
2025-03-24 |
Bayer Pharma AG |
Uso de indazoles sustituidos para el tratamiento y la prevencion de enfermedades en animales.
|
|
TW202340194A
(zh)
|
2017-02-16 |
2023-10-16 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
EP3600270B1
(en)
|
2017-03-31 |
2023-06-14 |
Aurigene Oncology Limited |
Compounds and compositions for treating hematological disorders
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
CN111194319A
(zh)
|
2017-10-19 |
2020-05-22 |
拜耳动物保健有限责任公司 |
稠合的杂芳族吡咯烷酮类化合物用于治疗和预防动物中的疾病的用途
|
|
HUE067356T2
(hu)
|
2017-10-31 |
2024-10-28 |
Curis Inc |
IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
GB201801226D0
(en)
|
2018-01-25 |
2018-03-14 |
Redx Pharma Plc |
Modulators of Rho-associated protein kinase
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
TWI842978B
(zh)
|
2018-07-13 |
2024-05-21 |
美商基利科學股份有限公司 |
衍生物
|
|
CA3119773A1
(en)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
SG11202108636SA
(en)
|
2019-02-11 |
2021-09-29 |
Merck Patent Gmbh |
Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US20230002361A1
(en)
*
|
2019-06-27 |
2023-01-05 |
Biogen Ma Inc. |
2h-indazole derivatives and their use in the treatment of disease
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
PE20220970A1
(es)
|
2019-08-30 |
2022-06-10 |
Rigel Pharmaceuticals Inc |
Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021066559A1
(en)
|
2019-10-02 |
2021-04-08 |
Kainos Medicine, Inc. |
N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US12421240B2
(en)
|
2019-10-31 |
2025-09-23 |
Hoffmann-La Roche Inc. |
Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
|
|
JP2023502087A
(ja)
|
2019-11-19 |
2023-01-20 |
エフ．ホフマン－ラ ロシュ アーゲー |
自己免疫疾患の処置のためのヒドロ－１Ｈ－ピロロ［１，２－ａ］ピラジン化合物
|
|
US12421229B2
(en)
|
2019-12-03 |
2025-09-23 |
Hoffmann-La Roche Inc. |
Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
KR20220145325A
(ko)
|
2019-12-17 |
2022-10-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
US11866405B2
(en)
|
2020-12-10 |
2024-01-09 |
Astrazeneca Ab |
Substituted indazoles as IRAK4 inhibitors
|
|
CN116867758A
(zh)
|
2020-12-30 |
2023-10-10 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
|
US12171768B2
(en)
|
2021-02-15 |
2024-12-24 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
US12357623B2
(en)
|
2021-03-03 |
2025-07-15 |
Rigel Pharmaceuticals, Inc. |
Method for treating a disease or condition using a pyrazole compound or formulation thereof
|
|
EP4319750A4
(en)
|
2021-04-08 |
2025-02-26 |
Curis, Inc. |
COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
KR20240020735A
(ko)
|
2021-05-07 |
2024-02-15 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Cdk2 분해제 및 그 용도
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
BR112023025403A2
(pt)
|
2021-06-25 |
2024-02-20 |
Korea Res Inst Chemical Tech |
Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo
|
|
CA3236265A1
(en)
|
2021-10-29 |
2023-05-04 |
William Leong |
Irak4 degraders and synthesis thereof
|
|
CA3243560A1
(en)
|
2022-01-31 |
2023-08-03 |
Kymera Therapeutics, Inc. |
Iraqi Degradation Agents and Their Uses
|
|
IL315677A
(en)
|
2022-03-23 |
2024-11-01 |
Rigel Pharmaceuticals Inc |
Pyrimid-2-yl-pyrazole compounds as irak inhibitors
|
|
KR102607237B1
(ko)
*
|
2023-06-07 |
2023-11-30 |
주식회사 젠센 |
신규한 트리아졸이 치환된 인다졸 유도체 및 이의 용도
|
|
CN121816348A
(zh)
*
|
2023-08-11 |
2026-04-07 |
深圳众格生物科技有限公司 |
一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
|